News

NEXI Stock Alert: NexImmune Delists From Nasdaq

NexImmune (NASDAQ: NEXI ) stock is no longer trading on the Nasdaq Exchange after the company's shares were delisted on Friday morning. This saw shares of NEXI stock removed from the Nasdaq Exchange when markets opened this morning.

07/12/2024

What Is Going on With NexImmune (NEXI) Stock Today?

Embattled biotechnology firm NexImmune (NASDAQ: NEXI ) is seeing shares skyrocket on Thursday, possibly due to anticipation around a lingering business matter. Due to severe financial struggles, management has sought to dissolve the enterprise.

07/11/2024

Profitability

Gross Profit Margin	33.46 %
Net Income Per EBT	79.83 %
Net Profit Margin	-2.47 %
Return on Assets	-1.21 %
Return on Equity	-3.07 %

Dividends

Dividend Yield (FWD)	Nil
Dividend Per Share	Nil
Payout Ratio	Nil
Payout Date	11/20/2019
Ex-Dividend Date	11/15/2019
Latest Announced Dividend	$2.23

Income Statement

Revenue	$1.17B
Gross Profit	$0.4B
Gross Profit Ratio	34.4%
EBITDA	$0.23B
Net Income	$-0.02B
EPS Diluted	-0.14

Balance Sheet

Long Term Debt	$0.98B
Total Liabilities	$1.52B
Total Equity	$0.94B
Total Investments	$0.01B
Total Debt	$1.17B
Total Assets	$2.46B

Cash Flow Statement

Net Income	$-0.02B
Inventory	$-0.01B
Dividends Paid	$-0B
Operating Cash Flow	$0.17B
Capital Expenditure	$-0.09B

Symbol Frequently Asked Questions

Is NexImmune, Inc. (NEXI) a buy, sell, or hold?

NexImmune, Inc. (NEXI) can sell. Click on Rating Page for detail.

What is NexImmune, Inc.'s stock price?

The price of NexImmune, Inc. (NEXI) is 0.0001 and it was updated on 2025-04-06 01:11:53.

Is NexImmune, Inc. (NEXI) overvalued or undervalued?

Currently NexImmune, Inc. (NEXI) is in undervalued.

News

From:

To:

Show entries

Search:

News
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. Tue, Feb. 06, 2024
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. Fri, Feb. 02, 2024
NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation Shares of NexImmune (NASDAQ: NEXI ) stock are skyrocketing higher ahead of the company's special meeting of stockholders. The meeting was initially set for Dec. 21 with a record date of Nov. 6. Tue, Jan. 09, 2024
Dear NEXI Stock Fans, Mark Your Calendars for Jan. 18 Inexplicably, shares of embattled immunotherapy specialist NexImmune (NASDAQ: NEXI ) are skyrocketing more than 190% despite efforts to dissolve the business. An earlier attempt to vote on the liquidation and dissolution of the biotechnology enterprise failed due to a lack of quorum. Wed, Jan. 03, 2024
NEXI Stock Halted: What's Going on With NexImmune Shares Today? Following a dramatic spike in shares yesterday, exchange operators at Nasdaq pulled the circuit breaker on NexImmune (NASDAQ: NEXI ). Though seemingly offering innovative solutions to disease treatment, the biotechnology firm has lost almost all its value since its initial public offering in 2021. Fri, Dec. 01, 2023

Showing 1 to 5 of 5 entries

Previous1Next

SEC Filings

Show entries

Search:

SEC Filings
NexImmune, Inc. (NEXI) - 25-NSE SEC Filings 09/06/2024
NexImmune, Inc. (NEXI) - EFFECT SEC Filings 08/29/2024
NexImmune, Inc. (NEXI) - S-8 POS SEC Filings 08/27/2024
NexImmune, Inc. (NEXI) - POS AM SEC Filings 08/27/2024
NexImmune, Inc. (NEXI) - 8-K - Current report SEC Filings 08/27/2024
NexImmune, Inc. (NEXI) - 8-K - Current report SEC Filings 08/15/2024
NexImmune, Inc. (NEXI) - 10-Q - Quarterly Report SEC Filings 08/07/2024
NexImmune, Inc. (NEXI) - DEFA14A SEC Filings 08/02/2024
NexImmune, Inc. (NEXI) - 8-K - Current report SEC Filings 08/02/2024
NexImmune, Inc. (NEXI) - DEFA14A SEC Filings 07/19/2024

Showing 1 to 10 of 155 entries

Previous1 2 3 4 5…16Next

Press Releases

Show entries

Search:

StockPrice Release
Neximmune announces closing of $3.67 million registered direct offering priced at-the-market under nasdaq rules 02/06/2024
Neximmune announces $3.67 million registered direct offering priced at-the-market under nasdaq rules 02/02/2024
Neximmune, yale, and jdrf extend research partnership for type 1 diabetes 10/24/2023
Neximmune announces presentations at the society for immunotherapy of cancer's 38th annual meeting 10/19/2023
Neximmune announces 1-for-25 reverse stock split 10/18/2023
Neximmune announces workforce reduction to enable continued aimtm nanoparticle platform development strategy 08/31/2023
Neximmune reports second quarter 2023 financial results and provides business updates 08/10/2023
Neximmune presents initial positive data from the nexi-001 phase 1 trial for relapsed/refractory post allo-hsct aml at the american society of clinical oncology 2023 annual meeting 06/05/2023
Neximmune announces poster presentation at the 2023 focis annual meeting 05/22/2023
Neximmune reports first quarter 2023 financial results and provides business updates 05/15/2023

Showing 1 to 10 of 41 entries

Previous1 2 3 4 5Next

More Headlines

Show entries

Search:

News
Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by more than 40% even as the Nasdaq 100 and S&P 500 indices pulled back. 12/01/2023
Why Is NexImmune (NEXI) Stock Up 353% Today? NexImmune (NASDAQ: NEXI ) stock is heading higher on Friday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases for filings with the Securities and Exchange Commission (SEC) that help explain why NEXI stock is up today. 12/01/2023
Why Is NexImmune (NEXI) Stock Down 10% Today? NexImmune (NASDAQ: NEXI ) stock is taking a beating on Monday after the clinical-stage biotechnology company continues with its wind-down plans. NexImmune announced last week the departure of members of its leadership team as it prepares to close up the business. 11/06/2023
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune's AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D). 10/24/2023
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual Meeting GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023. 10/19/2023
NexImmune Announces 1-for-25 Reverse Stock Split GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse stock split of the Company's common stock at a special meeting of the Company held on October 17, 2023. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market at 5:00 p.m. Eastern Time, on Wednesday, October 18, 2023. The Company's common stock will open for trading under a new CUSIP number 65344D 208 on The Nasdaq Capital Market on October 19, 2023, on a split-adjusted basis under the current ticker symbol "NEXI." The reverse stock split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. 10/18/2023
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that, in order to reduce its cash expenditures while continuing to pursue its existing strategic plan, its Board of Directors approved and its management is implementing an approximately 53% reduction in workforce, designed to reduce costs and extend the Company's cash. The realignment will reduce the Company's workforce from 47 to 22 full-time employees as of September 5, 2023. 08/31/2023
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates GAITHERSBURG, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today reported financial results for the second quarter of 2023. 08/10/2023
How to Identify Trends With Penny Stocks in 2023 Use these tips for identifying penny stocks trends in 2023 The post How to Identify Trends With Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 02/17/2023
Why Is NexImmune (NEXI) Stock Up 65% Today? NexImmune (NASDAQ: NEXI ) stock is rocketing higher on Thursday following the release of positive preclinical trial data. According to a press release from the company, preclinical data shows AIM ACT T cells are effective in aiding BiTE therapy. 02/16/2023

Showing 1 to 10 of 30 entries

Previous1 2 3Next

Unlock

NEXI Ratings Summary

Quant

Sell

NEXI Quant Ranking

Sector	Healthcare
Industry	Biotechnology
Quant Rating	Sell
Quant Score	2

Is NexImmune, Inc. (NEXI) a buy, sell, or hold?

What is NexImmune, Inc.'s stock price?

Is NexImmune, Inc. (NEXI) overvalued or undervalued?

Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping

Why Is NexImmune (NEXI) Stock Up 353% Today?

Why Is NexImmune (NEXI) Stock Down 10% Today?

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual Meeting

NexImmune Announces 1-for-25 Reverse Stock Split

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

How to Identify Trends With Penny Stocks in 2023

Why Is NexImmune (NEXI) Stock Up 65% Today?

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt